Get started
SUN PHARMACEUTICAL IND LSUN PHARMACEUTICAL IND LSUN PHARMACEUTICAL IND L

SUN PHARMACEUTICAL IND L

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

SUNPHARMA chart


Full chart

SUNPHARMA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.34 T‬ INR
Dividend yield (indicated)
0.74%
Price to earnings Ratio (TTM)
39.40
Basic EPS (TTM)
46.05 INR
Net income (FY)
‪95.76 B‬ INR
Revenue (FY)
‪478.63 B‬ INR
Shares float
‪1.02 B‬
Beta (1Y)
0.56

Employees


Employees (FY)
‪25.89 K‬
Change (1Y)
‪+1.13 K‬ +4.55%
Revenue / Employee (1Y)
‪18.48 M‬ INR
Net income / Employee (1Y)
‪3.70 M‬ INR

About SUN PHARMACEUTICAL IND L


Sector
Health Technology
CEO
Dilip Shantilal Shanghvi
Headquarters
Mumbai
Website
sunpharma.com
Founded
1983
ISIN
INE044A01036
FIGI
BBG000BV5H87
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SUNPHARMA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where SUNPHARMA is featured.

See all sparks 

Frequently Asked Questions


The current price of SUNPHARMA is 1,819.00 INR — it has increased by 0.24% in the past 24 hours. Watch SUN PHARMACEUTICAL IND L stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange SUN PHARMACEUTICAL IND L stocks are traded under the ticker SUNPHARMA.
SUNPHARMA stock has risen by 0.50% compared to the previous week, the month change is a 1.90% rise, over the last year SUN PHARMACEUTICAL IND L has showed a 46.69% increase.
We've gathered analysts' opinions on SUN PHARMACEUTICAL IND L future price: according to them, SUNPHARMA price has a max estimate of 2,450.00 INR and a min estimate of 1,600.00 INR. Watch SUNPHARMA chart and read a more detailed SUN PHARMACEUTICAL IND L stock forecast: see what analysts think of SUN PHARMACEUTICAL IND L and suggest that you do with its stocks.
SUNPHARMA reached its all-time high on Sep 30, 2024 with the price of 1,960.35 INR, and its all-time low was 2.25 INR and was reached on Jan 1, 1999. View more price dynamics on SUNPHARMA chart.
See other stocks reaching their highest and lowest prices.
SUNPHARMA stock is 1.59% volatile and has beta coefficient of 0.56. Track SUN PHARMACEUTICAL IND L stock price on the chart and check out the list of the most volatile stocks — is SUN PHARMACEUTICAL IND L there?
Today SUN PHARMACEUTICAL IND L has the market capitalization of ‪4.35 T‬, it has decreased by −1.39% over the last week.
Yes, you can track SUN PHARMACEUTICAL IND L financials in yearly and quarterly reports right on TradingView.
SUN PHARMACEUTICAL IND L is going to release the next earnings report on Feb 4, 2025. Keep track of upcoming events with our Earnings Calendar.
SUNPHARMA earnings for the last quarter are 12.70 INR per share, whereas the estimation was 11.99 INR resulting in a 5.97% surprise. The estimated earnings for the next quarter are 11.75 INR per share. See more details about SUN PHARMACEUTICAL IND L earnings.
SUN PHARMACEUTICAL IND L revenue for the last quarter amounts to ‪132.91 B‬ INR, despite the estimated figure of ‪133.16 B‬ INR. In the next quarter, revenue is expected to reach ‪132.92 B‬ INR.
SUNPHARMA net income for the last quarter is ‪30.40 B‬ INR, while the quarter before that showed ‪28.36 B‬ INR of net income which accounts for 7.21% change. Track more SUN PHARMACEUTICAL IND L financial stats to get the full picture.
SUN PHARMACEUTICAL IND L dividend yield was 0.83% in 2023, and payout ratio reached 33.82%. The year before the numbers were 1.17% and 32.56% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 25, 2024, the company has ‪25.89 K‬ employees. See our rating of the largest employees — is SUN PHARMACEUTICAL IND L on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SUN PHARMACEUTICAL IND L EBITDA is ‪139.13 B‬ INR, and current EBITDA margin is 26.12%. See more stats in SUN PHARMACEUTICAL IND L financial statements.
Like other stocks, SUNPHARMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUN PHARMACEUTICAL IND L stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SUN PHARMACEUTICAL IND L technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SUN PHARMACEUTICAL IND L stock shows the buy signal. See more of SUN PHARMACEUTICAL IND L technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.